SBBP News and Press, Strongbridge Biopharma plc From 05/12/21

Although Strongbridge Biopharma (SBBP) saw its Q1 net loss narrow by ~7.5% to $11.8M, shares are down 1.7% in premarket trading.For Q1, the rare diseases treatment company beat estimates for EPS but missed on revenue.Sales of neuromuscular drug KEVEYIS (dichlorphenamide) rose 25% ye...

Strongbridge Biopharma (SBBP): Q1 GAAP EPS of -$0.18 misses by $0.05.Revenue of $8.38B (+125537.2% Y/Y) beats by $8.37B.Shares -1.6% PM.Press Release For further details see: Strongbridge Biopharma EPS misses by $0.05, beats on revenue

~ Reports KEVEYIS ® (dichlorphenamide) First Quarter 2021 Revenue of $8.4 Million, a 25 Percent Increase Compared to $6.7 Million of Revenue During First Quarter of 2020 ~ ~ Reiterates Full-Year 2021 KEVEYIS ® (dichlorphenamide)&#...

DUBLIN, Ireland and TREVOSE, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced th...

SBBP has an approved product and a late-stage pipeline. However, Cushing's syndrome is a highly-differentiated market. Despite its positives, I'm not convinced about the long-term prospects of SBBP. For further details see: Strongbridge: Approved Drugs, Near-Term Catalys...

Strongbridge Biopharma (SBBP) rose ~21.5% in early after hours in reaction to the company announcement of a peer-reviewed publication of its results from Phase 3 SONICS study of Recorlev (levoketoconazole) in patients with Cushing’s syndrome.The manuscript titled “Levoketoc...

RECORLEV ® (levoketoconazole) Treatment Demonstrates Clinically Meaningful Improvements in Cortisol Control and Clinical Benefit in Patients with Cushing’s Syndrome and Comorbid Diabetes Mellitus DUBLIN, Ireland and TREVOSE, Pa., April 07, 2021 (GLOBE NEWSWIRE) -- ...

Strongbridge Biopharma ([[SBBP]] +5.9%) is on the rise in the morning hours after announcing the detailed results from the Phase 3 LOGICS study of Recorlev (levoketoconazole) in patients with endogenous Cushing’s syndrome.Data disclosed in a poster session at the ongoing Annu...

Some Of The Best Penny Stocks To Watch Early This Week This week has started stronger than the last & we have plenty of trending penny stocks to watch as a result. Last week the markets sold off, with tech continuing its move lower. What’s more, over the weekend, new virus da...

Support.com (SPRT) +271% as Greenidge Generation Holdings to go public via merger with the company.Seneca Biopharma (SNCA) +30%.Cemtrex (CETX) +21%.Marker Therapeutics (MRKR) +19%.Acer Therapeutics (ACER) +19%.Kansas City Southern (KSU) +17% as Canadian Pacific to buy the company fo...